We are live on ! Find out more
SVA

Sinovac Biotech, Ltd
SVA

Delisted

SVA was delisted on the 22nd of February, 2019.

Back to rankings

8 hedge funds and large institutions have $345M invested in Sinovac Biotech, Ltd in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% less capital invested

Capital invested by funds: $386M → $345M (-$41.2M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

73% less funds holding

Funds holding: 30 → 8 (-22)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 22

Holders
8
Holders Change
-22
Holders Change %
-73.33%
% of All Funds
0.12%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
–
Increased
1
Reduced
2
Closed
22
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
FGAM
Financial Gravity Asset Management
Texas
+$183K

Top Sellers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
-$38.2M
2
Renaissance Technologies
Renaissance Technologies
New York
-$1.54M
3
State Street
State Street
Massachusetts
-$1.04M
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$179K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$106K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$340M – – –
FGAM
2
Financial Gravity Asset Management
Texas
$3.2M +$183K +60 +6%
NAH
3
Neumann Advisory (HK)
Hong Kong
$2.04M – – –
TFA
4
Transamerica Financial Advisors
Florida
$1K – – –
HI
5
Horizon Investments
North Carolina
$336 – – –
VC
6
Vivo Capital
California
– -$38.2M -5,900,000 Closed
Renaissance Technologies
7
Renaissance Technologies
New York
– -$1.54M -2,375,841 Closed
State Street
8
State Street
Massachusetts
– -$1.04M -160,875 Closed
YMRC
9
Yorktown Management & Research Company
Virginia
– -$4.49K -149,786 Closed
Geode Capital Management
10
Geode Capital Management
Massachusetts
– -$179K -27,717 Closed
Susquehanna International Group
11
Susquehanna International Group
Pennsylvania
– -$106K -16,430 Closed
UBS Group
12
UBS Group
Switzerland
– -$58.8K -9,095 Closed
Morgan Stanley
13
Morgan Stanley
New York
– -$44.5K -6,879 Closed
JP Morgan Chase
14
JP Morgan Chase
New York
– -$19.4K -3,000 Closed
Wells Fargo
15
Wells Fargo
California
– -$10.7K -1,661 Closed
Group One Trading
16
Group One Trading
Illinois
– -$2.67K -412 Closed
Northwestern Mutual Wealth Management
17
Northwestern Mutual Wealth Management
Wisconsin
– -$660 -102 Closed

SVA Hedge Fund Activity: Q4 2023 in Review

8 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q4 2023, worth a combined $345M — down 11% from $386M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of SVA and 0 opened new positions — a net loss of 22 holders — while 2 trimmed existing stakes and 1 added.

The largest buyer was Financial Gravity Asset Management, adding an estimated $183K. The largest seller was Vivo Capital, exiting entirely with an estimated $38.2M sold.

  • 8 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q4 2023, down from 30 in Q3 2023.
  • Funds reported $345M of Sinovac Biotech, Ltd stock for Q4 2023, down 11% quarter-over-quarter.
  • 0 funds opened new Sinovac Biotech, Ltd positions in Q4 2023 and 22 closed out, a net change of -22 holders.
  • The largest Sinovac Biotech, Ltd buyer in Q4 2023 was Financial Gravity Asset Management, an estimated $183K added.
  • The largest Sinovac Biotech, Ltd seller in Q4 2023 was Vivo Capital, an estimated $38.2M sold.

Based on aggregated 13F filings for Q4 2023.